Detalhe da pesquisa
1.
A standardized intraperitoneal Glucantime™ for experimental treatment of cutaneous leishmaniasis caused by Leishmania amazonensis in BALB/c mice.
Exp Parasitol
; 236-237: 108259, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35427563
2.
The anti-Leishmania potential of bioactive compounds derived from naphthoquinones and their possible applications. A systematic review of animal studies.
Parasitol Res
; 121(5): 1247-1280, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35190878
3.
Plants of the Phytolaccaceae family with antimicrobial activity: A systematic review.
Phytother Res
; 36(9): 3505-3528, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35858779
4.
6,7-Dehydroroyleanone diterpene derived from Tetradenia riparia essential oil modulates IL-4/IL-12 release by macrophages that are infected with Leishmania amazonensis.
Parasitol Res
; 118(1): 369-376, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30519883
5.
Successful combined therapy with Glucantime™ and pentoxifylline for the nasal mucosal lesion recently developed in a leishmaniasis patient having untreated cutaneous lesion for seven decades.
Parasitol Int
; 85: 102422, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34280531
6.
Genetic variations in the human immune system influence susceptibility to tegumentary leishmaniasis: a systematic review and meta-analysis.
Expert Rev Clin Immunol
; 17(5): 513-537, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33749481
7.
Potential of Pluronics® P-123 and F-127 as nanocarriers of anti-Leishmania chemotherapy.
Acta Trop
; 192: 11-21, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30659806
8.
American tegumentary leishmaniasis: diagnostic and treatment challenges in a clinical case.
Rev Inst Med Trop Sao Paulo
; 60: e3, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29451600